EPTIS
BAM Logo

IC-9 Anti-CD20 therapy (rituximab) monitoring

[Monitorización de terapias anti CD20]

EPTIS factsheet 293131 | Last revision 2023-04-11 | URL: https://www.eptis.bam.de/pts293131 https://www.eptis.bam.de/pts293131

PT provider
PT provider GECLID-SEI (External Quality for Diagnostic Immunology Laboratories under the auspices of the Spanish Society for Immunology) GECLID-SEI (External Quality for Diagnostic Immunology Laboratories under the auspices of the Spanish Society for Immunology)
Based in Spain
Language(s) Spanish
Remarks
Keywords
Product groups Human test material
Testing fields Biology
Medical analysis
Technical details
Test item Tested property Testing method
Human blood CD19+ lymphocyte percentage -
CD20+ lymphocyte percentage -
plasmablasts' percentage -
B-lymphocytes (memory) -
Aims of the PT scheme
Target group of participants
Linked to specific legislation / standards
Additional, subsidiary aims
Number of participants 14
Accredited or otherwise reviewed by a 3rd party

Spanish Society for Immunology, Iberian Society for Flow Cytometry

Operation is commissioned / requested by Spanish Society for Immunology & Iberian Society for Flow Cytometry
Fees and frequency
Participation fee 302.31 EU
Regularly operated Yes (Twice a year)
Year of first operation 2017
Contact details of the PT provider
Provider Contact person
GECLID-SEI (External Quality for Diagnostic Immunology Laboratories under the auspices of the Spanish Society for Immunology)
Pº de Filipinos s/n
47007 Valladolid
Spain

Phone: +34 983 41 88 23 Ext.89673
Fax:
Web: https://www.geclid.es https://www.geclid.es
Dr. Carmen Martin
Phone: +34 686 247 331
Fax:
Email: responsable@geclid.es responsable@geclid.es
If you find any mistakes please contact the responsible EPTIS coordinator in Spain, Mr Miquel Navarro. Mr Miquel Navarro.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5